Prescription drug benefit manager Express Scripts Holding Co. (Nasdaq: ESRX) will no
longer cover Gilead Sciences Inc.'s (Nasdaq: GILD) hepatitis C treatment
Sovaldi beginning January 1. Shares of Express Scripts climbed $1.36 to close at $82.33 while Gilead stock plummeted $15.55 to close at $92.90.
Gilead's hepatits C treatment dropped by Express Scripts
December 22, 2014 at 16:33 PM EST